Pitfalls in the interpretation of CFTR variants in the context of incidental findings.


Journal

Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429

Informations de publication

Date de publication:
12 2019
Historique:
received: 06 03 2019
revised: 24 07 2019
accepted: 24 07 2019
pubmed: 28 7 2019
medline: 6 5 2020
entrez: 28 7 2019
Statut: ppublish

Résumé

Whole-exome/genome sequencing analyses lead to detect disease-causing variants that are unrelated to the initial clinical question. Irrespective of any actionable gene list, only pathogenic variants should be considered. The pathogenicity of 55 cystic fibrosis transmembrane conductance regulator (CFTR) variants of known various impacts was assessed by a group of experts by comparing data from specialized databases CFTR-France and CFTR2 with those of general clinical databases ClinVar and Human Gene Mutation Database (HGMD®) Professional and data aggregators VarSome and InterVar. The assessment of cystic fibrosis (CF) variants was correct with ClinVar and HGMD® Professional while less reliable with VarSome and InterVar. Conversely, the risk of overclassifying variants as CF-causing was up to 82% with HGMD® Professional. The concordance between data aggregators was only 50%. The use of general databases and aggregators is thus associated with a substantial risk of misclassifying variants. This evaluation may be extrapolated to other disease conditions and incites to remain cautious in interpreting and disclosing incidental findings.

Identifiants

pubmed: 31350925
doi: 10.1002/humu.23884
doi:

Substances chimiques

CFTR protein, human 0
Cystic Fibrosis Transmembrane Conductance Regulator 126880-72-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2239-2246

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Agathe Boussaroque (A)

Laboratoire de Génétique et Biologie Moléculaires, AP-HP, Hôpital Cochin, HUPC, Paris, France.

Anne Bergougnoux (A)

Laboratoire de Génétique Moléculaire, CHU de Montpellier, Montpellier, France.

Caroline Raynal (C)

Laboratoire de Génétique Moléculaire, CHU de Montpellier, Montpellier, France.

Marie-Pierre Audrézet (MP)

Laboratoire de Génétique Moléculaire, CHU de Brest, Brest, France.

Souphatta Sasorith (S)

Laboratoire de Génétique Moléculaire, CHU de Montpellier, Montpellier, France.

Claude Férec (C)

Laboratoire de Génétique Moléculaire, CHU de Brest, Brest, France.

Thierry Bienvenu (T)

Laboratoire de Génétique et Biologie Moléculaires, AP-HP, Hôpital Cochin, HUPC, Paris, France.

Emmanuelle Girodon (E)

Laboratoire de Génétique et Biologie Moléculaires, AP-HP, Hôpital Cochin, HUPC, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH